Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies-Reference-Cited by-同舟云学术

Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies

Published:2021-10-08 Issue:12 Volume:14 Page:1099-1114
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Bisht Kamlesh¹,Walker Brian²,Kumar Shaji K.³,Spicka Ivan⁴,Moreau Philippe⁵,Martin Tom⁶,Costa Luciano J.⁷,Richter Joshua⁸,Fukao Taro¹,Macé Sandrine⁹,van de Velde Helgi¹

Affiliation:

1. Oncology Therapeutic Area, Sanofi Research and Development, Cambridge, MA, USA

2. Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN, USA

3. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

4. First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic

5. Department of Hematology, University Hospital of Nantes, Nantes, France

6. Department of Medicine, University of California, San Francisco, CA, USA

7. Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA

8. Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

9. Sanofi Research and Development, Sanofi, Vitry-Sur-Seine, France

Funder

Sanofi, Cambridge, MA, USA

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2021.1983427

Reference129 articles.

1. An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome

2. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

3. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities

4. Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A predictive risk‐scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South‐Western China;Cancer Medicine;2024-09

2. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN;Blood Cancer Journal;2024-07-08

3. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies;American Society of Clinical Oncology Educational Book;2024-06

4. Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature;Expert Opinion on Biological Therapy;2024-05-03

5. The numerous facets of 1q21⁺ in multiple myeloma: Pathogenesis, clinicopathological features, prognosis and clinical progress (Review);Oncology Letters;2024-04-09